%0 Journal Article
%T The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
%A Ho Yeong Lim
%A Jeeyun Lee
%A Joon Oh Park
%A Ju Sun Kim
%A Jung Eun Kim
%A Kyung Kim
%A Seung Tae Kim
%A Won Ki Kang
%A Young Suk Park
%J Journal of Cancer
%D 2017
%I Ivyspring International Publisher
%R 10.7150/jca.19458
%X Background: Anti-EGFR therapies have been recommended for advanced colorectal cancer (CRC) with wild-type RAS and PIK3CA mutation. However, PIK3CA mutations are a poor prognostic marker and a negative predictor of response to anti-EGFR therapies in RAS wild-type CRC. Therefore, new and advanced treatment strategies are needed for personalized medical treatment of patients with wild-type RAS and PIK3CA mutation.
%K Colon cancer
%K cetuximab
%K RAS wild-type
%K PIK3CA mutation.
%U http://www.jcancer.org/v08p2713.htm